Tetrabutylphosphonium bromide

We are Tetrabutylphosphonium bromide CAS:3115-68-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


English Name: Tetrabutylphosphonium bromide
Synonyms:Phosphonium, tetrabutyl-, bromide
Tetrabutylphosphonium bromide
Tetra-N-butylphosphonium bromide
Molecular Formula: C16H36BrP
Molecular Weight: 339.33
CAS No.: 3115-68-2
Purity: 99%
 
Technical Information

Appearance:	Purity:
NMR: Passed	null
Solubility:	Insolubility:
Impurity content: (1) Water content: < 1000 ppm

 
Physics-Chemistry Properties

Melting point: 104°C	Decomposition temperature: 310°C
Conductivity:	Electrochemical window:
Viscosity:	Density:

 
Our company has been engaged in the R&D, production of ionic liquids and related technologies for more than ten years. Since 2007, our company has supplied ionic liquid reagents to customers, and can provide customers with ionic liquid products from grams to hundreds of tons. The main product series are: Imidazolium ionic liquids, single-substituted Im ionic liquids, Disubstituted Im ionic liquids, Tri-Substituted Im ionic liquids, Pyrilidinium ionic liquids, Ammonium ionic liquids, Phosphonium ionic liquids, Pyrrolidinium ionic liquids, Piperidinium ionic liquids, Functionized ionic liquids, Vinyl-Based ionic liquids, Hydroxyl-Based ionic liquids, Ether-Based ionic liquids, Ester-Based ionic liquids, Carboxyl-Based ionic liquids, Nitrile-Based ionic liquids, Amido-Based ionic liquids, SulfoAcid-Based ionic liquids, Benzyl-Based ionic liquids, Guanidine-Based ionic liquids, Oxonium salts



Related News: The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.3-bromo-3'-cloro-1,1'-bifenilo CAS:844856-42-4 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).64695-84-7 “And also to make sure that your meat is cooked thoroughly before consuming.”5-(4-Fluorophenyl)-5-oxopentanoic acid The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.